Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf Accessed 19, 2019.
   Google Scholar
• Seebri® Breezhaler® [summary of product characteristics]. Seebri breezhaler inhalation powder, hard capsules 44 mcg. Available from: https://www.medicines.org.uk/emc/medicine/27138 Accessed 417, 2019.
   Google Scholar
• SEEBRI™ NEOHALER® [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc. Available from: https://www.seebri.us/Seebri-Prescribing-Information.pdf Accessed November 14, 2019.
   Google Scholar
• Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16(1):135. doi:10.1186/s12890-016-0291-427724909
   PubMed Web of Science ®Google Scholar
• Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58–72. doi:10.3109/15412555.2011.63004722292598
   PubMedGoogle Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371. doi:10.1378/chest.127.1.33515654001
   PubMed Web of Science ®Google Scholar
• George M. Adherence in asthma and COPD: new strategies for an old problem. Respir Care. 2018;63(6):818–831. doi:10.4187/respcare.0590529794213
   PubMed Web of Science ®Google Scholar
• Ari A. Patient education and adherence to aerosol therapy. Respir Care. 2015;60(6):941–955. doi:10.5152/ejp.2014.0008726070585
   PubMed Web of Science ®Google Scholar
• Toy E, Beaulieu N, McHale J, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.00620880687
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794. doi:10.1183/13993003.01794-201628182569
   PubMed Web of Science ®Google Scholar
• Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585–2596. doi:10.2147/COPD.S11403427799757
   PubMed Web of Science ®Google Scholar
• Amin AN, Ganapathy V, Roughley A, Small M. Confidence in correct inhaler technique and its association with treatment adherence and health status among US patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2017;11:1205–1212. doi:10.2147/PPA.S14013928744110
   PubMed Web of Science ®Google Scholar
• Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018;2018:1–9. doi:10.1155/2018/9473051
   Web of Science ®Google Scholar
• Sharafkhaneh A, Wolf RA, Goodnight S, Hanania NA, Make BJ, Tashkin DP. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013;10(4):482–492. doi:10.3109/15412555.2013.77330223875742
   PubMedGoogle Scholar
• Taffet GE, Donohue JF, Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging. 2014;9:23–30. doi:10.2147/CIA.S5299924376347
   PubMed Web of Science ®Google Scholar
• Ari A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. Eurasian J Pulmonol. 2014;16:1–7. doi:10.5152/ejp.2014.00087
   Google Scholar
• Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol. 2015;8(4):479–501. doi:10.1586/17512433.2015.105815426109098
   PubMed Web of Science ®Google Scholar
• YUPELRI® [prescribing information]. Morgantown, WV: Mylan Specialty LP Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?type=display&setid=6dfebf04-7c90-436a-9b16-750d3c1ee0a6 Accessed 1114, 2019.
   Google Scholar
• National Center for Biotechnology Information. PubChem Database. Revefenacin, CID=11753673, Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Revefenacin Accessed 1120, 2019.
   Google Scholar
• National Center for Biotechnology Information. PubChem Database. Tiotropium bromide, CID=5487426, Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tiotropium-bromide Accessed 1120, 2019.
   Google Scholar
• National Center for Biotechnology Information. PubChem Database. Umeclidinium bromide, CID=11519069, Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Umeclidinium-bromide Accessed 1120, 2019.
   Google Scholar
• Ji Y, Husfeld C, Pulido-Rios MT, et al. Duration by design: discovery of revefenacin, the first-in-class nebulized once-daily bronchodilator for the treatment of patients with COPD [abstract]. Chest. 2016;150(4 Suppl):970A. doi:10.1016/j.chest.2016.08.1074
   Web of Science ®Google Scholar
• Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018;6(3):e00400. doi:10.1002/prp2.40029736245
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective Inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–250. doi:10.1124/jpet.113.20355423685545
   PubMed Web of Science ®Google Scholar
• Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–79. doi:10.1016/j.pupt.2017.10.00328987804
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov. A 7-day cross-over study of QD (once daily) and BID (twice daily) TD-4208 in chronic obstructive pulmonary disease (COPD). Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT2109172?term=Revefenacin&rank=9 Accessed 56, 2019.
   Google Scholar
• Pudi KK, Barnes CN, Moran EJ, Haumann B, Kerwin E. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182. doi:10.1186/s12931-017-0647-129096627
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Feldman G, Pudi KK, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials. Chronic Obstr Pulm Dis. 2019;6(2). doi:10.15326/jcopdf.6.2.2018.0152
   Web of Science ®Google Scholar
• Donohue J, Kerwin E, Sethi S, et al. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019;153:38–43. doi:10.1016/j.rmed.2019.05.01031150963
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6(4):321–331. doi:10.15326/jcopdf.6.4.2019.0137
   Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP24383418
   PubMed Web of Science ®Google Scholar
• Donohue J, Pendyala S, Barnes C, Moran E, Crater G. Improvements in health status with revefenacin, a once-daily long-acting muscarinic antagonist for nebulization: changes in St George’s Respiratory Questionnaire and COPD Assessment Test in replicate 3-Month Studies [abstract]. Chest. 2017;152(4):A819. doi:10.1016/j.chest.2017.08.850
   Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• Donohue J, Kerwin E, Barnes C, et al. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in COPD patients with markers of more severe disease [abstract]. CHEST. 2018;154(4):736A–737A. doi:10.1016/j.chest.2018.08.665
   Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.141628933581
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS28481631
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179. doi:10.1089/jamp.2012.098723025451
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.018328848933
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.0002480717898020
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC28406710
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Donohue JF, Feldman G, Sethi S, et al. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019;57:101808. doi:10.1016/j.pupt.2019.101808.
   Google Scholar
• Goodman N, Morgan M, Nikander K, Hinch S, Coughlin S. Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease. J Aerosol Med Pulmo Drug Deliv. 2010;23(Suppl 1):S61–S70. doi:10.1089/jamp.2009.0767
   PubMed Web of Science ®Google Scholar
• Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care–the SPiRiva Usual CarE (SPRUCE) study. Respir Res. 2007;8(45). doi:10.1186/1465-9921-8-91
   Web of Science ®Google Scholar
• Calverley P, Rennard S, Clerisme-Beaty E, Metzdorf N, Zubek V, ZuWallack R. Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. Respir Res. 2016;17:27. doi:10.1186/s12931-016-0340-926971242
   PubMed Web of Science ®Google Scholar
• Barjaktarevic IZ, Arredondo AF, Cooper CB. Positioning new pharmacotherapies for COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1427–1442. doi:10.2147/COPD.S8375826244017
   PubMed Web of Science ®Google Scholar
• Montuschi P, Macagno F, Valente S, Fuso L. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20(12):1464–1476. doi:10.2174/092986731132012000222963553
   PubMed Web of Science ®Google Scholar
• Fuso L, Mores N, Valente S, Malerba M, Montuschi P. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem. 2013;20(12):1477–1495. doi:10.2174/092986731132012000323409722
   PubMed Web of Science ®Google Scholar
• LONHALA® MAGNAIR® [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Available from: https://www.lonhalamagnair.com/LonhalaMagnair-Prescribing-Information.pdf Accessed November 14, 2019.
   Google Scholar
• Brovana® [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc Available from: http://www.brovana.com/brovana-approved-labeling-text.pdf Accessed 513, 2019.
   Google Scholar
• PERFOROMIST® [prescribing information]. Morgantown, WV: Mylan Specialty L.P Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af Accessed 513, 2019.
   Google Scholar
• PULMICORT RESPULES® [highlights of prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP Available from: https://www.azpicentral.com/pulmicortrespules/pulmicortrespules.pdf#page=1 Accessed 915, 2019.
   Google Scholar
• Melani A, Di Gregorio A. Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Monaldi Arch Chest Dis. 1999;54(3):224–227.10441974
   PubMedGoogle Scholar
• Paggiaro P, Vagaggini B, Di Franco A, Zingoni M, Fano M, Biraghi M. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. Respiration. 2006;73(5):603–609. doi:10.1159/00008981616293958
   PubMed Web of Science ®Google Scholar
• Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250. doi:10.1016/j.rmed.2017.07.01128838685
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260. doi:10.1016/j.rmed.2017.08.02028919143
   PubMed Web of Science ®Google Scholar